Selective transport of blood-borne interleukin-1α into the posterior division of the septum of the mouse brain

doi:10.1016/0006-8993(95)00913-B

Brain Research

Volume 700, Issues 1–2, 27 November 1995, Pages 83-88

https://doi.org/10.1016/0006-8993(95)00913-B Get rights and content

Abstract

Film autoradiography was used to demonstrate the transport and sites of accumulation of blood-borne radioiodinated interleukin-1α (Il-1α) and other cytokines into the brain after intravenous administration. [¹²⁵I]Il-1α, [¹²⁵I]Il-1β, [¹²⁵I]interleukin-1 receptor antagonist (Il-1ra), and [¹²⁵I]tumor necrosis factor-α (TNFα) labeled the chroid plexus and the capillary network 30 min after injection into the blood, suggesting that these areas may serve as sites of blood-to-brain transport. [¹²⁵I]Il-1α, but not [¹²⁵I]Il-1β, [¹²⁵I]Il-1ra, [¹²⁵I]TNFα, or [¹²⁵I]interleukin-2 (Il-2), was also found localized to the caudal region of the septal nuclei. Only unlabeled Il-1α was able to inhibit this accumulation. These findings provide further evidence for the passage of select cytokines across the blood-brain barrier (BBB) and are the first to identify a target site within the central nervous system (CNS) for a transported cytokine.

Reference (28)

BanE. et al.
Receptors for interleukin-1 (α and β) in the mouse brain: mapping and neuronal localization in hippocampus
Neuroscience
(1991)
BanksW.A. et al.
Blood-to-brain transport of interleukin links the immune and central nervous systems
Life Sci.
(1991)
BanksW.A. et al.
Bidirectional transport of interleukin-1 alpha across the blood-brain barrier
Brain Res. Bull.
(1989)
BanksW.A. et al.
Interleukin-1α in blood has direct access to cortical brain cells
Neurosci. Lett.
(1993)
BanksW.A. et al.
Saturable transport of the peptides RC-160 and Tyr-MIF-1 by different parts of the blood-brain barrier
Brain Res. Bull.
(1994)
ContestabileA. et al.
Cholinergic and GABAergic forebrain projections to the habenula and nucleus interpeduncularis: surgical and kainic acid lesions
Brain Res.
(1983)
GutierrezE.G. et al.
Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier
J. Neuroimmunology
(1994)
HartB.L.
Biological basis for the behavior of sick animals
Neurosci. Biobehav. Rev.
(1988)
KentS. et al.
Sickness behavior as a new target for drug development
Trends Pharmacol. Sci.
(1992)
MorleyB.J.
The interpeduncular nucleus
Int. Rev. Neurobiol.
(1986)

OtternessI.G. et al.

The effects of continuous administration of interleukin-1α in the rat

Physiol. Behav.

(1988)

Plata-SalamanC.R.

Immunoregulators in the nervous system

Neurosci. Biobehav. Rev.

(1991)

PretoriusH.T. et al.

Binding of Tyr-MIF-1 to isolated brain capillaries

Brain Res. Bull.

(1986)

SutherlandR.J.

The dorsal diencephalic conduction system: a review of the anatomy and functions of the habenular complex

Neurosci. Biobehav. Rev.

(1982)

Cited by (52)

Drug delivery to the brain in Alzheimer's disease: Consideration of the blood-brain barrier
2012, Advanced Drug Delivery Reviews
Citation Excerpt :
Transporters for many of the peptides and regulatory proteins typically have the added complexity of having a heterogenous distribution [152]; this characteristic could be used to target drug delivery to specific areas of the brain. For example, the BBB transporter for interleukin-1 is especially concentrated at the posterior division of the septum, the leptin transporter at the arcuate nucleus of the hypothalamus, and the transporter for APP-directed antisense at the hippocampus [7,121,153,154]. From clinical use to preclinical study, a few drugs used in AD are known to take advantage of transport systems.
The successful treatment of Alzheimer's disease (AD) will require drugs that can negotiate the blood–brain barrier (BBB). However, the BBB is not simply a physical barrier, but a complex interface that is in intimate communication with the rest of the central nervous system (CNS) and influenced by peripheral tissues. This review examines three aspects of the BBB in AD. First, it considers how the BBB may be contributing to the onset and progression of AD. In this regard, the BBB itself is a therapeutic target in the treatment of AD. Second, it examines how the BBB restricts drugs that might otherwise be useful in the treatment of AD and examines strategies being developed to deliver drugs to the CNS for the treatment of AD. Third, it considers how drug penetration across the AD BBB may differ from the BBB of normal aging. In this case, those differences can complicate the treatment of CNS diseases such as depression, delirium, psychoses, and pain control in the AD population.
Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury
2011, European Journal of Pain
Citation Excerpt :
The finding that neuropathic pain was attenuated in IL-1raTG mice, which over-express IL-1ra under the control of glial fibrillary acidic protein (GFAP) promoter (Lundkvist et al., 1999; Wolf et al., 2003), suggest that the role of IL-1 in the development of neuropathic pain is mediated via receptors located within the CNS, as GFAP is expressed mostly in astrocytes within the brain and spinal cord. As proteins of the IL-1 family can cross the BBB either by specific transporters (Banks et al., 1994; Banks et al., 1989; Banks et al., 1991; Maness et al., 1995), or as the result of changes in BBB permeability induced by IL-1β application (Blamire et al., 2000; Didier et al., 2003; Ferrari et al., 2004). Moreover, peripherally administrated IL-1ra was recently demonstrated to penetrate the BBB (Clark et al., 2008).
Neuropathic pain is a chronic pain state resulting from peripheral nerve injury, characterized by hyperalgesia and allodynia. We have reported that mice with genetic impairment of IL-1 signaling display attenuated neuropathic pain behavior and ectopic neuronal activity. In order to substantiate the role of IL-1 in neuropathic pain, WT mice were implanted subcutaneously with osmotic micropumps containing either IL-1ra or vehicle. Two days following the implantation, two models of neuropathic pain were used; partial nerve injury (spinal nerve transection, SNT), or complete nerve cut (spinal neuroma model). Mechanosensitivity was assessed seven consecutive days following SNT, and on day 7 recordings of spontaneous ectopic activity were performed. In the spinal nerve neuroma model, autotomy scores were recorded up to 35 days. Vehicle-treated mice developed significant allodynia and autotomy, and clear ectopic activity (4.1 ± 1.1% of the axons); whereas IL-1ra-treated mice did not display allodynic response, displayed delayed onset of autotomy and markedly reduced severity of autotomy scores, and displayed reduced spontaneous activity (0.8 ± 0.4% of the axons). To test whether IL-1 is involved in maintenance of mechanical allodynia, a separate group of WT mice was treated with a single injection of either saline or IL-1ra four days following SNT, after the allodynic response was already manifested. Whereas saline-treated mice displayed robust allodynia, acute IL-1ra treatment induced long-lasting attenuation of the allodynic response. The results support our hypothesis that IL-1 signaling plays an important role in neuropathic pain and in the ectopic neuronal activity that underling its development.
Blood-Brain Barrier Transport of Cytokines
2008, NeuroImmune Biology
Citation Excerpt :
For example, the mouse transports across its BBB murine IL-1α, murine IL-1β, and human IL-1α [2]. Neither rat nor mouse, however, transports human IL-1β across their BBBs [81–83]. Likewise, the mouse transports murine, but not human, TNF across its BBB [71,84,85].
Cytokine interactions with the blood–brain barrier (BBB) and blood–cerebrospinal fluid (B-CSF) barrier are an integral part of neuroimmune interactions. These barriers constitute potential limitations or restrictions against the free exchange of humoral message-bearing molecules residing in blood, CSF, and extracellular fluid (ECS) within brain and non-neural body fluid compartments. Many cytokines are transported across the BBB, and there are unique transporters for groups and families of cytokines that enable movements from blood to brain and the converse. This chapter reviews these transport movements in either direction for their behavioral effects, their species specificity and the alterations in transport that may occur or can be demonstrated in health and after pathological processes. The rate at which these cytokine transporters act is shown to not be static and is known to vary diurnally, among different strains of animals and with different brain locations. Cytokines are shown to affect the transport of other substances across the BBB, including viruses and regulatory proteins such as insulin. Secretion of cytokines by cells that comprise the BBB is also reviewed in order to illustrate the range of cytokine interactions with the barriers.
Corticotropin-releasing factor (CRF)-induced behaviors are modulated by intravenous administration of teneurin C-terminal associated peptide-1 (TCAP-1)
2007, Peptides
The teneurin C-terminal associated peptides (TCAP) are a recently discovered family of bioactive peptides that can attenuate aspects of the behavioral stress responses of rats. Because TCAP has some structural similarity to the corticotropin-releasing factor (CRF) family of peptides, and modulates elements of the stress response, TCAP may act to modulate CRF actions in vivo. This hypothesis was tested by investigating anxiety-related behaviors in male rats following repeated intravenous (IV) TCAP-1 administration with either an acute intracerebroventricular (ICV) or IV CRF challenge. TCAP-1 alone did not affect behavioral responses significantly, however did significantly affect CRF-regulated behaviors depending on CRF's mode of injection. In both the elevated plus-maze and the open field tests, TCAP-1 had an anxiolytic effect on ICV CRF responses as indicated by decreased stretched-attend postures in the elevated plus maze (p < 0.05), and increased center time and center entries in the open field (p < 0.05). However, prior TCAP-1 treatment has an anxiogenic effect on the IV CRF-induced behaviors (decreased center entries and total distance in the open field (p < 0.05)). TCAP-1's actions are not mediated through acute changes in glucocorticoid levels and may occur via a central action in the brain. A fluorescently (FITC)-labeled TCAP-1 analog was IV-administered to investigate whether IV TCAP-1 has the potential to regulate central mechanisms by crossing the blood–brain barrier. FITC-TCAP-1 was detected in blood vessels and fibers in the brain indicating that uptake into the brain is a possible route for its interaction with CRF and its receptors. Thus, TCAP may modulate CRF-associated behaviors by a direct action in the CNS.
Leptin, Insulin and Blood-Brain Barrier Relations in Obesity
2005, The Metabolic Syndrome at the Beginning of the XXI Century: A Genetic and Molecular Approach
Transport of Cytokines and Neurotrophins across the Blood-Brain Barrier and Their Regulation after Spinal Cord Injury
2004, Blood-Spinal Cord and Brain Barriers in Health and Disease
Cytokines and neurotrophic peptides/proteins have various degrees of permeation across the blood–brain barrier (BBB) by way of simple diffusion or by specific transport systems. The significance of studies of transport systems is obvious because of the biological impact of these molecules on the central nervous system (CNS) in health and disease. We have characterized the pharmacokinetic characteristics of some stable cytokines and neurotrophic peptides/proteins in mice after intravenous administration or in the setting of in situ brain perfusion. The fate of the radiolabeled compounds in blood and CNS and their interactions with the BBB are summarized. Identification of BBB permeation and the modulating factors will aid in application of the cytokines and neurotrophic peptides/proteins as therapeutic agents. The particular case of spinal cord injury (SCI) is discussed in further detail. SCI is related to time– and region–specific changes of the BBB function. Tumor necrosis factor–a (TNF–α), a cytokine with dual actions in regeneration of the spinal cord, has a slow basal influx into the brain and spinal cord. After SCI, the increase in the entry of TNF–α to the CNS differs from leakage after BBB disruption and is related to upregulation of the transport system in a unique temporal and regional pattern. In this way, SCI at different locations with different types and severity of lesions is associated with different patterns of upregulation of the transport system. Overall, the current results indicate that the BBB is a dynamic barrier that regulates the availability of cytokines and neurotrophic peptides/proteins to the CNS in normal physiological conditions and that the BBB is also modulated by pathological processes such as SCI.

View all citing articles on Scopus

View full text

Selective transport of blood-borne interleukin-1α into the posterior division of the septum of the mouse brain

Abstract

Neuroscience

Life Sci.

Brain Res. Bull.

Neurosci. Lett.

Brain Res. Bull.

Brain Res.

J. Neuroimmunology

Neurosci. Biobehav. Rev.

Trends Pharmacol. Sci.

Int. Rev. Neurobiol.

Physiol. Behav.

Neurosci. Biobehav. Rev.

Brain Res. Bull.

Neurosci. Biobehav. Rev.